Immunic, Inc.
- IMUX
- NASDAQ
- Biotechnology
- Oral Immunotherapy
- Autoimmune Disease Therapeutics
$6.96
Today −0.14%Quote Oct 19, 2026, 04:10 PM UTC
−32.66%over the last month
Max drawdown −38.6%From 1-month high −35.7%3 months −53.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Immunic
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
100
Market value
$95.0M
Quote Oct 19
Floor
$6.66
4.3% below price
Resistance
$7.43
6.7% above price
Price vs analyst targets
12 analysts
Lowest target
$19.00Highest target
$45.00
$19.00Highest target
$45.00
- Price $6.96
- Average target $28.67
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 312% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about IMUXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free